Abstract

ROLE OF NEBIVOLOL IN THE TRANSITION OF ACUTE KIDNEY INJURY TO CHRONIC KIDNEY DISEASE

Menna A. Elbrolosy*, Mirhan N. Makled and Manar G. Helal

ABSTRACT

Cisplatin (Cis), a chemotherapeutic used to treat solid tumors, can cause acute kidney damage (AKI). Recent studies suggest a link between AKI and chronic kidney disease (CKD). Clinical and animal research indicates that AKI can lead to CKD progression even after complete renal function recovery. Nebivolol (Neb) is a third-generation selective β-1 blocker shown to have renoprotective effect in previous studies. Present study investigated the role of Neb on Cis-induced AKI-CKD transition. Model of AKI-CKD transition was induced by two cycles (5 consecutive days each) of 2.5 mg/kg/day of Cis intraperitoneally with sixteen days between the two cycles. Neb was administrated daily for 42 consecutive days (10 mg/kg orally). Blood and urine samples were collected at two different time points to assess levels of serum creatinine and urinary protein excretion during disease progression. At the end of the experiment, kidney tissues were collected to assess histological alterations. Neb administration could amend tubular and glomerular damage as revealed by decreased serum creatinine, urinary protein excretion, and hematoxylin and eosin (H&E) histopathological alterations. Additionally, Neb reduced renal fibrosis as evidenced by Masson’s Trichome -stained renal sections. In conclusion, Neb could exhibit a role in deferring Cis-induced AKI-CKD transition by amelioration of glomerular and tubular damage and fibrosis.

Keywords: .